Blue Jet Healthcare Limited has informed the Exchange regarding a press release dated May 14, 2025, titled "Press Release Blue Jet Healthcare for the quarter and financial year ended March 31, 2025".
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Blue Jet Healthcare reported record Q4 FY25 revenue of Rs. 3,404 million, up 85.1% YoY and 6.9% QoQ. Q4 EBITDA jumped 163.7% YoY to Rs. 1,400 million, with margins expanding sharply to 41.1% from 28.8% a year ago. For full-year FY25, revenue grew 44.7% to Rs. 10,300 million and PAT rose 86.4% to Rs. 3,052 million, driven mainly by the Pharmaceutical Intermediate & API business. The Board proposed a final dividend of Rs. 1.2 per share and is seeking shareholder approval to raise up to Rs. 15,000 million through QIP, preferential issue, or private placement. The company also commercialized Gadolinium-based Contrast Media Intermediates, was allotted a new plot at Dahej III, and received a tax demand of Rs. 1,933.86 million (under appeal).
The strong topline growth, sharp margin expansion, and record profitability are positive signals likely to support the stock. However, the proposed Rs. 15,000 million fundraise could raise dilution concerns, and the large tax demand under appeal is a key risk to watch.